Pimagedine, also known as aminoguanidine, is an investigational drug for the treatment of diabetic nephropathy that is no longer under development as a drug. [1] Pimagedine functions …

2007年11月18日 · Pimagedine has been developed by Synvista Therapeutics, Inc for the treatment of diabetic kidney disease. It is an advanced glycation end product inhibitor which …

2003年11月1日 · Aminoguanidine (AG) is a prototype therapeutic agent for the prevention of formation of advanced glycation endproducts. It reacts rapidly with alpha,beta-dicarbonyl …

Hydrazine, a compound recognized for its carcinogenic and genotoxic properties, presents a significant threat to human health via environmental exposure and drug metabolism. The …

Pimagedine (aminoguanidine HCl) has been shown to be an effective agent in reducing the severity of the structural and functional alterations associated with experimental diabetic …

Pimagedine has been developed by Synvista Therapeutics, Inc for the treatment of diabetic kidney disease. It is an advanced glycation end product inhibitor which manages diabetic …

Pimagedine is a nucleophilic hydrazine. It was shown to inhibit diamine oxidase (histaminase), which catalyzes the oxidative deamination of diamines histamine and putrescine. Pimagedine …

2021年10月14日 · Pimagedine has been developed by Synvista Therapeutics, Inc for the treatment of diabetic kidney disease. It is an advanced glycation end product inhibitor which …

This substance record has relationships which can be visualized as a network with other substance records. A simplified representation of that network can be interactively explored …

Pimagedine是由Synvista和安斯泰来制药集团研发的一种小分子药物，是一种NOS2抑制剂和晚期糖基化终末产物抑制剂。 目前该药物最高研发阶段为终止，用于治疗糖尿病肾病。